A vaccine offering new hope for millions of Alzheimer’s disease patients, their physicians and caregivers has passed a Phase 1 safety trial, according to the creator of the vaccine, biotech firm AXON Neuroscience. This makes AXON the first company to successfully complete a Phase 1 study with an active immunotherapy treatment aimed at diseased tau proteins that cause neural degeneration in Alzheimer’s patients. The vaccine is designed to stimulate patients‘ immune systems to attack these diseased proteins, and halt the progress of Alzheimer’s disease.
Michal Novak, AXON’s chief science officer and company co-founder, said that “the first phase of clinical trials shows that we’ve managed to build a robust and safe vaccine for AD. That was the task of the first phase, which was met 100 percent.“
AXON will present its results from the Phase 1 study at the Alzheimer’s Association International Conference (AAIC) at the AXON Neuroscience sponsored Symposium which will be held on July 22, 2015 at 6:00 PM in Marriott Marquis Hotel, Washington, DC.